Earlier this year, Lawrence Sher, MD, FAAP, Associate Medical Director of Peninsula Research Associates, a Headlands Research site, co-authored a phase 3 study evaluating the mRNA-1010 quadrivalent influenza vaccine.
This large-scale trial demonstrated that a single 50-μg dose of mRNA-1010 elicited stronger immune responses than licensed standard-dose and high-dose influenza vaccines, with a favorable safety profile and no major safety concerns.
These findings highlight the potential of mRNA-based technology to transform seasonal influenza prevention.
Read more in Vaccine.